TYN604 is a monoclonal antibody designed for the treatment of autoimmune diseases, specifically targeting the interleukin-6 receptor (IL-6R). By inhibiting IL-6 signaling, TYN604 aims to reduce inflammation and modulate the immune response in conditions such as rheumatoid Arthritis and other inflammatory disorders. It is currently being investigated in clinical trials to evaluate its safety and efficacy.